Search This Blog

Thursday, May 2, 2024

Novo Nordisk raises outlook fuelled by obesity drug demand

 Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly.

The company has quadrupled its U.S. supply of starter doses Wegovy since December, Senior Vice President Negelle Morris told Reuters this week.

At least 20,000 new U.S. patients are starting on the weekly injection each week, reflecting the company's efforts to ramp up output, she said.

The small raise to the outlook and forecast-beating results underscore Wegovy's success and Novo's lead in the fast-growing obesity drug market.

Novo's growth on the back of the phenomenal success of Wegovy has nonetheless been held back by its ability to meet runaway demand for the weekly injection.

The company also faces fierce competition from U.S. rival Eli Lilly as it rolls out its Zepbound therapy in new markets. It launched in the United States in December and in Germany, Poland and Britain this year.

The company said it now expects sales growth this year of between 19% and 27% in local currencies, compared to the previously guided range for 18% to 26% growth.

Operating profit growth this year is now seen at between 22% and 30% in local currencies, slightly up from its previous forecast of 21% to 29%.

Novo reported first-quarter earnings before interest and taxation (EBIT) of 31.8 billion Danish crowns ($4.57 billion), above the 29 billion forecast by analysts in a LSEG poll this week and up 27% from a year ago.

Sales of Novo's obesity care products, including Wegovy, rose 41% in local currencies in the first quarter, to 11 billion crowns.

Wegovy sales totalled 9.4 billion Danish crowns between January and March, down from 9.6 billion crowns in the previous quarter and 107% higher than the same quarter a year ago, in local currencies.

The boost to starter U.S. doses comes as the company spends billions to boost output of Wegovy and keep up with explosive demand.

A year ago, Novo began limiting the number of U.S. patients who can start treatment by reducing the supply of the lowest three doses of the appetite-suppressing weekly injection.

In January, Novo said it was more than doubling supply of lower strength or "starter" Wegovy doses in the U.S. that month compared with recent ones. Still, shortages in the U.S. persist.

https://www.yahoo.com/news/obesity-drugmaker-novo-nordisks-q1-053403065.html

US official urges China, Russia to declare only humans, not AI, control nuclear weapons

 A senior U.S. official on Thursday urged China and Russia to match declarations by the United States and others that only humans, and never artificial intelligence, would make decisions on deploying nuclear weapons.

State Department arms control official Paul Dean told an online briefing that Washington had made a "clear and strong commitment" that humans had total control over nuclear weapons, adding that France and Britain had done the same.

"We would welcome a similar statement by China and the Russian Federation," said Dean, principal deputy assistant secretary in the Bureau of Arms Control, Deterrence and Stability.

"We think it is an extremely important norm of responsible behaviour and we think it is something that would be very welcome in a P5 context," he said, referring to the five permanent members of the United Nations Security Council.

Dean's remarks come as the administration of U.S. President Joe Biden tries to deepen separate discussions with China over both nuclear weapons policy and the growth of artificial intelligence.

The Chinese defence ministry did not immediately respond to a request for comment.

The spread of artificial intelligence technology surfaced during sweeping talks between U.S. Secretary of State Antony Blinken and China's Foreign Minister Wang Yi in Beijing on April 26.

The two sides agreed to hold their first bilateral talks on artificial intelligence in the coming weeks, Blinken said, adding that they would share views on how best to manage risks and safety surrounding the technology.

As part of normalising military communications, U.S. and Chinese officials resumed nuclear weapons discussions in January, but formal arms control negotiations are not expected any time soon.

China, which is expanding its nuclear weapons capabilities, urged in February that the largest nuclear powers should first negotiate a no-first-use treaty between each other.

https://www.yahoo.com/news/us-official-urges-china-russia-044924612.html

Taiwan says may be hard to attend WHO assembly, Blinken offers support

It will be hard for Taiwan to attend this year's World Health Organization annual assembly, and it hopes more countries will support its presence, the island's foreign minister said on Thursday after the United States pressed for an invite.

Taiwan is excluded from most international organisations because of objections by China, which considers the democratically governed island its own territory.

Taiwan attended the World Health Assembly (WHA) as an observer from 2009 to 2016 under the administration of then-President Ma Ying-jeou, who signed landmark trade and tourism agreements with China. But Beijing began blocking Taiwan's participation in 2017 after President Tsai Ing-wen won office.

Speaking to reporters in parliament, Taiwan Foreign Minister Joseph Wu noted a Wednesday statement from U.S. Secretary of State Antony Blinken in which he said the United States "strongly encourages" the WHO to reinstate Taiwan's invitation.

"When it comes to attending this year's WHA there may be some difficulties, but we are continuing to work hard, as before, to get more countries to support us," Wu said, without elaborating on those problems.

This year's WHA starts May 27, just a week after Taiwan president-elect Lai Ching-te takes office. China has a strong dislike of Lai, who it believes is a dangerous separatist and has rebuffed his repeated calls for talks.

Taiwan, which is allowed to attend some technical WHO meetings, says its exclusion hindered efforts to fight the COVID-19 pandemic.

Blinken's statement said the United States commended the WHO for taking steps to engage Taiwan more meaningfully in its technical work over the past year and for improving lines of communication.

"Yet Taiwan's continued exclusion from this preeminent global health forum undermines inclusive global public health cooperation and security," he added. "Inviting Taiwan to observe the WHA is a critically important step toward affirming the WHO's goal of 'Health for All'."

Neither China's foreign ministry nor the WHO immediately responded to a request for comment.

China has in recent years ramped up diplomatic and military pressure against Taiwan to force the island to accept Chinese sovereignty.

Taiwan's government rejects China's claims and says only the island's 23 million people can decide their future, and that Beijing has no right to speak for or represent Taiwan on the international stage.

https://www.yahoo.com/news/taiwan-says-may-hard-attend-023223023.html

Japan's Warning For America

 by Michael Wilkerson via The Epoch Times,

Last week, Japan saw its currency, the yen, rapidly depreciate against the U.S. dollar and other world currencies to near record low levels. This drew the attention of financial markets and other observers, and—in some quarters—led to panic. There was concern that Japan, a formerly great nation now increasingly viewed as the “sick man of Asia,” was on the brink of a currency and financial markets crisis.

It wasn’t so long ago that Japan was the envy of the world. Japan’s postwar recovery and subsequent economic miracle produced by the 1980s the world’s second-largest economy after the United States. Numerous Japanese multinational corporations were admired by the business world as a result of their growth, efficiency, and managerial discipline. The state and big business were closely aligned in what appeared an unstoppable formula. Flush with cash and confidence, Japanese companies and investors were aggressively expansionist, acquiring market share, trophy properties, resources, and businesses in the United States and elsewhere. Much like concerns about China today, fears then abounded that Japan would overtake the United States as the global economic leader.

These fears were unfounded. “Japan Inc.” was a house built on a faulty foundation. Overly accommodative easy money, along with high leverage throughout the financial and corporate sectors, facilitated a massive stock market and real estate bubble, which eventually burst in 1990. The crash led to a depression from which Japan has never recovered, even after three decades. The question is, why not? Herein lies a lesson for the United States.

Repeated government bailouts of failing financial and industrial companies have perpetuated Japan’s crisis. Japan’s leaders and policies have repeatedly blocked the process of creative destruction, which—if allowed to run its course and cleanse the system—would have been a massive stimulus to entrepreneurship and economic vitality. However, rather than allow capitalism to work, the Japanese system doomed the country to a generation of stagnation.

As a result, Japan has endured three “lost decades” of weak economic growth, diminished purchasing power, lower and lower standards of living, loss of prestige and influence in the global community, and an aging population that the island nation’s resources are straining to support.

Japan now has the world’s highest government debt-to-GDP ratio, at 264 percent. Japan’s banks are walking zombies, unable to grow or lend because they have never restructured their balance sheets to clean up massive piles of debt left over from excesses of previous decades. The Bank of Japan (BOJ) holds government bonds and other assets equal to 127 percent of Japan’s GDP, the highest ratio of any central bank in the world. This portfolio resulted in over $70 billion in unrealized losses for the BOJ in six months of 2023 alone.

The Japanese yen has devalued against the U.S. dollar by more than 30 percent in just three years since 2021. Since the global financial crisis 2008–09, the yen has lost 75 percent of its value against gold. Because of Japan’s high reliance on imports, this loss of purchasing power has translated directly into a substantially lower standard of living for the Japanese people. In theory, Japan could support the yen by raising interest rates, but this is a political, monetary, and fiscal impossibility.

Decades of easy money policies are a central culprit and cause of this slow-moving trainwreck.

The Bank of Japan only began raising interest rates this March, some three years after the United States and the European Union brought their own easy money policies to an end. This was the first time the BOJ has raised rates since 2007, a move that pulled the official rate out of negative territory. Nonetheless, with inflation now approaching 2 percent, a short-term policy rate of zero to 0.1 percent means that real rates remain around negative 2 percent. This serves as an additional tax on Japanese households and an intended stimulus to spend today rather than save for tomorrow.

Money essentially is free in Japan, but no one can afford to borrow it, even if the banks can manage to lend it. The BOJ and the entire banking system stand in the penumbra of insolvency. Only Japan’s decade-long zero interest-rate policy has allowed Japan’s decrepit financial system to continue to stand following the 2008 financial crisis and the effects of COVID economic shutdowns. Japan cannot afford to raise interest rates to support its currency more than nominally above the zero bound without substantially raising debt service costs and exploding losses. This would bring the entire rickety system to the ground.

A growing economy might help ease the burden, but Japan’s economy is moribund. This is not surprising, as meaningful growth is impossible under mountains of debt. GDP shrank by 0.8 percent in the third quarter and eked out 0.1 percent growth in the fourth quarter. While the country thus barely escaped technical recession (two consecutive quarters of GDP decline), Japan hasn’t posted GDP growth above 2 percent in more than 20 years, save for two rebound quarters after the global shocks of the financial crisis and COVID.

Japan represents a slow-moving demographic disaster. Japan has the oldest median population of any major country in the world and the lowest fertility rate at 1.37. Japan’s fertility rate has been below the minimum population replacement rate (2.1) for 40 years, meaning that the country is both aging and losing economic productivity, and it is probably too late to reverse it.

This all represents a grave warning to the United States.

The U.S. government is chasing Japan for the ignoble title of most indebted nation. Overly indebted nations cannot grow. With federal government debt to GDP of 129 percent, a ratio which is increasing rapidly, the United States is now the fourth most indebted country in the world. Debt is growing more quickly now because the federal government refuses to wean itself off of deficit spending, including an additional $1.7 trillion in 2023, which must be funded by new debt, as must over $1 trillion in interest expense. This debt—and the cost to service it—acts as a drag on our economy. Deficit spending and the borrowing required to support it crowds out private market investment and financings.

Rather than let more insolvent banks and unprofitable firms fail, U.S. monetary policy since at least the 2008 financial crisis has propped up bad business models—and the asset values of otherwise worthless investments—by subsidizing the cost of capital well below the natural rate of interest. In a nation that has been the standard bearer and exporter of capitalism for more than two centuries, socialistic government policies are preventing capitalism from working at home. This will eventually catch up with our financial markets and economy, just as it did for Japan.

It is not just shortsighted monetary and financial policy that threatens U.S. competitiveness.

If Americans’ worsening attitudes toward the importance of marriage and children do not reverse course dramatically, the United States will face the same demographic fate as Japan. The fertility rate in the United States has been in decline since at least 2008, and reached a record low of 1.62 in 2023. This is well below the replacement rate, and thus unsustainable.

Progressives point to declining fertility rates and aging populations to justify mass illegal immigration, but this is a red herring. Bringing tens of millions of unskilled, uneducated, and culturally unassimilated migrants into the nation is not a benefit but rather an untenable burden on social infrastructure, an enervating drain on economic productivity, and an unbearable tax on legal citizens.

At least Japan got that part right.

https://www.zerohedge.com/markets/japans-warning-america

Wednesday, May 1, 2024

Uncovering the secret of long-lived stem cells

 Nothing lives forever, but compared to other cells in the body, hematopoietic stem cells (HSCs) are remarkably long-lived. HSCs are blood-forming cells -- they give rise to rapidly dividing progenitor cells, which in turn generate hundreds of billions of cells to fulfill the daily demand of oxygen-delivering red blood cells, disease-fighting white blood cells and clot-forming platelets.

HSCs typically remain dormant within the bone marrow, yet they possess the ability to activate and replenish blood cells continuously, maintaining a relatively youthful profile throughout the life of an organism. What is the secret of long-lived HSCs that wards off the effects of aging? A team led by researchers at Baylor College of Medicine revealed in Nature Cell Biology that the enzyme cyclophilin A, which is produced in large amounts in HSCs, is key for these cells to retain their regenerative potential and avert the effects of aging.

Long live the stem cells!

"A driving force of cellular aging is the accumulation of proteins that have reached the end of their useful life," said corresponding author Dr. André Catic, assistant professor and CPRIT Scholar in Cancer Research in the Huffington Center on Aging at Baylor. "With age, proteins tend to misfold, aggregate and accumulate inside the cell, which leads to toxic stress that can disrupt cell function."

Cells that frequently engage in cell division, like progenitor cells, can dispose of protein aggregates through dilution. On the other hand, long-lived HSCs, which do not divide often, face the problem of the accumulation of misfolded proteins and subsequent toxic stress. Nevertheless, HSCs remain impervious to aging. How do they do it?

"Understanding the molecular mechanisms that contribute to HSC aging not only contributes to the field of normal HSC biology, but also may have significant clinical relevance for cancer treatment," said co-first author of the work, Dr. Lauren Maneix, who was at the Catic lab while working on this project.

Molecular chaperones at work

Previous studies have shown that mammalian cells express several hundreds of molecular chaperones, proteins that preserve or change the three-dimensional conformation of existing proteins. Cyclophilins, one of the most abundant chaperones, have been implicated in the aging process. However, how they affect cellular proteins has not previously been studied.

Working with mice, the researchers first characterized the protein content of HSCs and discovered that cyclophilin A is a prevalent chaperone. Further experiments showed that the expression of cyclophilin A was significantly decreased in aged HSCs, and genetically eliminating cyclophilin A accelerated natural aging in the stem cell compartment. In contrast, reintroducing cyclophilin A into aged HSCs enhanced their function. Together, these findings support cyclophilin A as a key factor in the longevity of HSCs.

Connecting cyclophilin A, intrinsically disordered proteins and HSC longevity

Next, the team investigated the proteins with which cyclophilin A interacts, preserving their stability. "We found that proteins enriched in intrinsically disordered regions are frequent targets of the chaperone," Catic said.

Intrinsically disordered proteins naturally change their 3-D conformation to interact with different proteins, nucleic acids or other molecules. Consequently, proteins rich in intrinsically disordered regions regulate many cellular processes by promoting specific activities between molecules. "Due to their flexible nature, intrinsically disordered proteins are inherently prone to aggregation. Cyclophilin A supports these proteins in fulfilling their functions and simultaneously prevents them from clumping," Catic said.

Furthermore, the findings suggest that cyclophilin A interacts with intrinsically disordered proteins from the moment of their synthesis. "As these proteins are being made, cyclophilin A makes sure they keep the appropriate conformations and are maintained at sufficient levels," Catic said. "Genetic depletion of cyclophilin A results in stem cells distinctively lacking intrinsically disordered proteins."

"For the first time, our study showed that producing disordered proteins and maintaining the structural diversity of the proteins in a cell plays a role in HSC aging," Maneix said.

Co-first author Polina Iakova, Charles G. Lee, Shannon E. Moree, Xuan Lu, Gandhar K. Datar, Cedric T. Hill, Eric Spooner, Jordon C. K. King, David B. Sykes, Borja Saez, Bruno Di Stefano, Xi Chen, Daniela S. Krause, Ergun Sahin, Francis T. F. Tsai, Margaret A. Goodell, Bradford C. Berk and David T. Scadden also contributed to this study.


Journal Reference:

  1. Laure Maneix, Polina Iakova, Charles G. Lee, Shannon E. Moree, Xuan Lu, Gandhar K. Datar, Cedric T. Hill, Eric Spooner, Jordon C. K. King, David B. Sykes, Borja Saez, Bruno Di Stefano, Xi Chen, Daniela S. Krause, Ergun Sahin, Francis T. F. Tsai, Margaret A. Goodell, Bradford C. Berk, David T. Scadden, André Catic. Cyclophilin A supports translation of intrinsically disordered proteins and affects haematopoietic stem cell ageingNature Cell Biology, 2024; 26 (4): 593 DOI: 10.1038/s41556-024-01387-x

Clogged arteries worsened by cells that behave like cancer cells

 Columbia University researchers have found cells inside clogged arteries share similarities with cancer and aggravate atherosclerosis, raising the possibility that anticancer drugs could be used to treat atherosclerosis and prevent heart attacks.

Their study found that smooth muscle cells that normally line the inside of our arteries migrate into atherosclerotic plaques, change their cell identity, activate cancer genes, and proliferate inside the plaques.

"Our study shows that these transformed muscle cells are driving atherosclerosis, opening the door to new ways to treat the disease, potentially with existing cancer drugs," says Muredach Reilly, MD, the Florence and Herbert Irving Endowed Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons and director of Columbia's Irving Institute for Clinical and Translational Research.

The study, published April 30 in Circulation, was led by Reilly and Huize Pan, now an assistant professor of medicine at Vanderbilt University Medical Center, who conducted the research when he was an associate research scientist at Columbia.

DNA damage, hyperproliferation

Atherosclerosis is the major cause of heart attacks and stroke around the world and occurs when fat deposits build up inside the arteries. Atherosclerosis can be reduced with a healthy diet or drugs called statins that slow or reverse the buildup of deposits.

Previous studies had found that smooth muscle cells metamorphose into different types of cells inside these atherosclerotic plaques and multiply to make up most cells within the plaques.

Yet until now, few studies had examined the cancer-like properties of the cells and if these changes contributed to atherosclerosis. To learn more, Reilly and Pan closely tracked the development of transformed smooth muscle cells in mice with atherosclerosis and sampled plaques of people with atherosclerosis.

They found striking parallels between changes in the smooth muscle cells and tumor cells, including hyperproliferation, resistance to cell death, and invasiveness

DNA damage, another hallmark of cancer, accumulated in the mouse and human smooth muscle cells and appears to accelerate atherosclerosis, the researchers found. The researchers could further accelerate atherosclerosis in mice by introducing a genetic mutation that increased DNA damage within the smooth muscle cells. Vascular tissue from healthy mice and people had no signs of smooth muscle cells with the DNA damage found in atherosclerotic plaques.

Reilly adds that they found no evidence of metastasis. "The cells stay inside existing plaques, which makes us think that they behave mostly like benign tumor cells, but more work needs to be done in humans and animal models to address this hypothesis," he says.

Treating atherosclerosis like cancer

If atherosclerosis is driven by cancer-like cells, anticancer therapies may be a potential new way to treat or prevent the disease.

The researchers explored that idea by treating atherosclerotic mice with a common cancer drug, niraparib, that targets cells with DNA damage. The drug significantly decreased the size of the atherosclerotic plaques and improved plaque stability (stable plaques reduce the odds of having a heart attack).

"This suggests that cancer drugs like niraparib could both prevent the buildup of plaques and treat atherosclerosis once its established," Reilly says. "But it's important to note that the experiment with niraparib was proof of a principle and does not directly translate to clinical use."

Other cancer drugs may also have benefits. "We need more work to select the best targets, safest targeted therapies, and vascular delivery strategies," Reilly says. "And we need to determine if different people have different types of DNA damage and mutations that drive the disease, and, if so, we can use that information to develop personalized therapies to treat atherosclerosis," Reilly says.

"Statins are very effective in many people at reducing atherosclerosis and preventing hearts attacks, but some people still have substantial cardiovascular risk. We think more research into the cancer-like properties of atherosclerosis will lead to new treatment options for these patients."


Journal Reference:

  1. Huize Pan, Sebastian E. Ho, Chenyi Xue, Jian Cui, Quinian S. Johanson, Nadja Sachs, Leila S. Ross, Fang Li, Robert A. Solomon, E. Sander Connolly, Virendra I. Patel, Lars Maegdefessel, Hanrui Zhang, Muredach P. Reilly. Atherosclerosis Is a Smooth Muscle Cell–Driven Tumor-Like DiseaseCirculation, 2024; DOI: 10.1161/CIRCULATIONAHA.123.067587

Brain circuit IDd in mice that controls body's inflammatory reactions

 The brain can direct the immune system to an unexpected degree, capable of detecting, ramping up and tamping down inflammation, shows a new study in mice from researchers at Columbia's Zuckerman Institute.

"The brain is the center of our thoughts, emotions, memories and feelings," said Hao Jin, PhD, a co-first author of the study published online today in Nature. "Thanks to great advances in circuit tracking and single-cell technology, we now know the brain does far more than that. It is monitoring the function of every system in the body."

Future research could identify drugs that can target this newfound brain circuit to help treat a vast range of disorders and diseases in which the immune system goes haywire.

"This new discovery could provide an exciting therapeutic venue to control inflammation and immunity," said Charles S. Zuker, PhD, the study's senior author, a principal investigator at Columbia's Zuckerman Institute and a Howard Hughes Medical Institute investigator.

Recent work from the Zuker lab and other groups is revealing the importance of the body-brain axis, a vital pathway that conveys data between the organs and the brain. For example, Dr. Zuker and his colleagues discovered that sugar and fat entering the gut use the body-brain axis to drive the craving and strong appetite for sugary and fatty foods.

"We found all these ways in which the body is informing the brain about the body's current state," said co-first author Mengtong Li, PhD, a postdoctoral researcher in the Zuker lab. "We wanted to understand how much farther the brain's knowledge and control of the body's biology went."

The scientists looked for connections the brain might have with inflammation and innate immunity, the defense system shared by all animals and the most ancient component of the immune system. Whereas the adaptive immune system remembers previous encounters with intruders to help it resist them if they invade again, the innate immune system attacks anything with common traits of germs. The relative simplicity of innate immunity lets it respond to new insults more quickly than adaptive immunity.

Prior studies in humans revealed that electrically stimulating the vagus nerve -- a bundle of thousands of nerve fibers linking the brain and the body's internal organs -- could reduce the response linked to a specific inflammatory molecule. However, much remained unknown about the nature of this body-brain system: for instance, the generality of the brain's modulation of immunity and the inflammatory response, the selective lines of communication between the body and the brain, the logic of the underlying neural circuit, and the identity of the vagal and brain components that monitor and regulate inflammation.

The Zuker lab turned to a bacterial compound that sets off innate immune responses. The scientists found that giving this molecule to mice activated the caudal nucleus of the solitary tract, or cNST, which is tucked inside the brainstem. The cNST plays a major role in the body-brain axis and is the primary target of the vagus nerve.

The scientists showed that chemically suppressing the cNST resulted in an out-of-control inflammatory response to the immune insult: levels of pro-inflammatory molecules released by the immune system were more than three times higher than usual, and levels of anti-inflammatory immune compounds were roughly three times lower than normal. In contrast, artificially activating the cNST reduced pro-inflammatory molecule levels by nearly 70 percent and increased anti-inflammatory chemical levels almost tenfold.

"Similar to a thermostat, this newfound brain circuit helps increase or decrease inflammatory responses to keep the body responding in a healthy manner," said Dr. Jin, who started this study as a postdoctoral researcher in Dr. Zuker's lab. Dr. Jin is now a tenure track investigator at the National Institute of Allergy and Infectious Diseases. "In retrospect, it makes sense to have a master arbiter controlling this vital response."

Previous vagus nerve stimulation research in humans suggests the findings go beyond mice. The new research may also be in line with thousands of years of thought on the potential importance of the mind on the body.

"A lot of psychosomatic effects could actually be linked to brain circuits telling your body something," Dr. Jin noted.

The scientists identified the specific groups of neurons in the vagus nerve and in the cNST that help detect and control pro- and anti-inflammatory activity. "This opens up a new window into how the brain monitors and modulates body physiology," said Dr. Zuker, a professor of biochemistry, molecular biophysics and neuroscience at Columbia's Vagelos College of Physicians and Surgeons.

Discovering ways to control this newfound brain circuit may lead to novel therapies for common auto-immune diseases such as rheumatoid arthritis, type I diabetes, multiple sclerosis, neurodegenerative diseases, lupus, inflammatory bowel disease and Crohn's disease, as well as conditions such as long COVID syndrome, immune rejection of transplanted organs, and the potentially deadly outbursts known as cytokine storms that COVID infections can trigger.

Autoimmune diseases may affect roughly one in 10 individuals, a 2023 Lancet study suggested. In the United States alone, autoimmune diseases may cost the economy $100 billion annually, a figure that may be a gross underestimate, according to the Autoimmune Associatio

Harnessing the activity of this circuit may make a difference across a broad range of conditions affecting the immune system, and help treat dysregulated inflammatory states in people suffering from immune diseases and disorders, Drs. Jin and Li said.


Journal Reference:

  1. Hao Jin, Mengtong Li, Eric Jeong, Felipe Castro-Martinez, Charles S. Zuker. A body–brain circuit that regulates body inflammatory responsesNature, 2024; DOI: 10.1038/s41586-024-07469-y